Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Status:
Recruiting
Trial end date:
2023-07-20
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and
interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that
cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such
as nivolumab, may help the body's immune system attack the cancer and may interfere with the
ability of tumor cells to grow and spread. Chemotherapy drugs, such as fluorouracil, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Interferon alpha 2b may help
stimulate the immune system to fight cancer. Giving nivolumab, fluorouracil, and interferon
alpha 2b may work better in treating unresectable fibrolamellar cancer compared to
fluorouracil and interferon alpha 2b alone.